Angiotensin II relaxations of bovine adrenal cortical arteries: Role of angiotensin ii metabolites and endothelial nitric oxide

Hypertension

Volumn 52, Issue 1, 2008, Pages 150-155

  Gauthier, Kathryn M ^a   Zhang, David X ^a   Cui, Lijie ^a   Nithipatikom, Kasem ^a   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Angiotensin (1 7); Angiotensin III; Angiotensin IV; Mass spectrometry

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LOSARTAN; NITRIC OXIDE SYNTHASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); IMIDAZOLE DERIVATIVE; NITRIC OXIDE; PEPTIDE FRAGMENT; PYRIDINE DERIVATIVE; VASOCONSTRICTOR AGENT;

ADRENAL ARTERY; ADRENAL CORTEX; ANIMAL TISSUE; ARTERY; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENCY; INCUBATION TIME; MASS SPECTROMETRY; METABOLISM; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANIMAL; CATTLE; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASOCONSTRICTION; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADRENAL CORTEX; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN III; ANIMALS; ARTERIES; CATTLE; ENDOTHELIUM, VASCULAR; IMIDAZOLES; LOSARTAN; NITRIC OXIDE; PEPTIDE FRAGMENTS; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 46449115611     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.104158     Document Type: Article

References (31)

1. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
2. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007;73:463-469.
3. Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol. 2004;217:67-74.
4. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens. 2007;25:25-35.
5. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007;50:112-119.
6. Tipnis SR, Hooper NM, Hyde R, Karran EH, Christie G, Turner AJ. A human homolog of angiotensin converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
7. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47: 515-521.
8. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
9. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383: 45-51.
10. Santos AS, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens. 2007;16:122-128.
11. TodaN, Ayajiki K, OkamuraT. Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev. 2007;59:54-87.
12. Ardaillou R, Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int. 1997;52:1458-1468.
13. Ruiz-Ortega M, Esteban V, Egido J. The regulation of the inflammatory response through nuclear factor- κβ pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovascul Med. 2007;17:19-25.
14. Hinson JP, Vinson GP, Whitehouse BJ. The relationship between perfusion medium flow rate and steroid secretion in the isolated perfused rat adrenal gland in situ. J Endocrinol. 1986;111:391-396.
15. Gauthier KM, Zhang DX, Edwards EM, Holmes B, Campbell WB. Angiotensin II dilates bovine adrenal cortical arterioles: role of endothe-lial nitric oxide. Endocrinology. 2005;146:3319-3324.
16. Hanke CJ, Holmes BB, Xu Y, Nithipatikom K, Campbell WB. Endothe-lium-derived steroidogenic factor enhances angiotensin II-stimulated al-dosterone release by bovine zona glomerulosa cells. Endocrinology. 2007;148:317-323.
17. Cui L, Nithipatikom K, Campbell WB. Simultaneous analysis of angio-tensin peptides by LC-MS and LC-MS/MS: metabolism by bovine adrenal endothelial cells. Anal Biochem. 2007;369:27-33.
18. Campbell WB, Gomez-Sanchez CE, Adams BV, Schmitz JM, Itskovitz HD. Attenuation of angiotensin II and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979;64:1552-1557.
19. Campbell WB, Pettinger WA. Organ specificity of angiotensin II and des-aspartyl angiotensin II in the conscious rat. J Pharmacol Exp Ther. 1976;198:450-456.
20. Zhang DX, Gauthier KM, Campbell WB. Characterization of vasoconstrictor responses in small bovine adrenal cortical arteries in vitro. Endocrinology. 2004;145:1571-1578.
21. Zhang DX, Gauthier KM, Falck JR, Siddam A, Campbell WB. Steroid-producing cells regulate arterial tone of adrenal cortical arteries. Endocrinology. 2007;148:3569-3576.
22. Vinson GP, Hinson JP, Toth IE. The neuroendocrinology of the adrenal cortex. J Neuroendocrinol. 1994;6:235-246.
23. Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelial vascular endothelium. Hypertension. 1992;19(suppl II):II56-II61.
24. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532:107-110.
25. Tirapelli CR, Fukada SY, de Godoy MAF, de Oliveira AM. Analysis of the mechanisms underlying the vasorelaxant action of angiotensin II in the isolated rat carotid. Life Sci. 2006;78:2676-2682.
26. Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh E, Umemura S, Ishii M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension. 2000;35:998-1001.
27. Sampaio WO, Nascimento AAS, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol. 2003;284:H1985-H1994.
28. Burns KD. The emerging role of angiotensin-converting enzyme-2 in the kidney. Curr Opin Nephrol Hypertens. 2007;16:116-121.
29. Bassett JR, West SH. Vascularization of the adrenal cortex: its possible involvement in the regulation of steroid hormone release. Microsc Res Tech. 1997;36:546-557.
30. Hanke CJ, Campbell WB. Endothelial cell nitric oxide inhibits aldoste-rone synthesis in zona glomerulosa cells: modulation by oxygen. Am J Physiol Endocrinol Metab. 2000;279:E846-E854.
31. Rosolowsky LJ, Campbell WB. Endothelial cells stimulate aldosterone production from bovine adrenal zona glomerulosa cells. Am J Physiol Endocrinol Metab. 1994;266:E107-E117.